{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:00:24Z","timestamp":1791892824170,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ymgme.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T06:02:48Z","timestamp":1441605768000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States"],"prefix":"10.1016","volume":"117","author":[{"given":"Manisha","family":"Balwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Andrew","family":"Burrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Charrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ruskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2015.09.002_bb0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","article-title":"Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements","volume":"163","author":"Grabowski","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.09.002_bb0010","series-title":"OMMBID: The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher disease","author":"Grabowski","year":"2013"},{"key":"10.1016\/j.ymgme.2015.09.002_bb0015","series-title":"Advances in Human Genetics","first-page":"377","article-title":"Gaucher disease: enzymology, genetics, and treatment","author":"Grabowski","year":"1993"},{"issue":"18","key":"10.1016\/j.ymgme.2015.09.002_bb0020","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2015.09.002_bb0025","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ymgme.2011.08.004","article-title":"Therapeutic approaches to bone pathology in Gaucher disease: past, present and future","volume":"104","author":"Goker-Alpan","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2015.09.002_bb0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2015.09.002_bb0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1096-7192(02)00122-1","article-title":"Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy","volume":"77","author":"Mistry","year":"2002","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.002_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"4 Suppl. 5","key":"10.1016\/j.ymgme.2015.09.002_bb0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"issue":"10","key":"10.1016\/j.ymgme.2015.09.002_bb0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s002560000276","article-title":"Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume","volume":"29","author":"Terk","year":"2000","journal-title":"Skelet. Radiol."},{"issue":"5","key":"10.1016\/j.ymgme.2015.09.002_bb0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008814105603","article-title":"The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study","volume":"7","author":"Damiano","year":"1998","journal-title":"Qual. Life Res."},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.002_bb0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Quality of life related to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual. Life Res."},{"issue":"6","key":"10.1016\/j.ymgme.2015.09.002_bb0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1023\/A:1008878425167","article-title":"The impact of Gaucher disease and its treatment on quality of life","volume":"7","author":"Hayes","year":"1998","journal-title":"Qual. Life Res."},{"issue":"6","key":"10.1016\/j.ymgme.2015.09.002_bb0070","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin. Genet."},{"issue":"6 Suppl. 8","key":"10.1016\/j.ymgme.2015.09.002_bb0075","first-page":"1","article-title":"Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion","volume":"10","author":"Mistry","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.002_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.002_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.002_bb0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.002_bb0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.002_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"45","key":"10.1016\/j.ymgme.2015.09.002_bb0105","doi-asserted-by":"crossref","first-page":"19,473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.ymgme.2015.09.002_bb0110","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.12651","article-title":"Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy","volume":"93","author":"de Fost","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.002_bb0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ymgme.2015.09.002_bb0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"8","key":"10.1016\/j.ymgme.2015.09.002_bb0125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"10.1016\/j.ymgme.2015.09.002_bb0130","series-title":"US Prescribing Information","author":"Zavesca (miglustat)","year":"2014"},{"issue":"43","key":"10.1016\/j.ymgme.2015.09.002_bb0135","doi-asserted-by":"crossref","first-page":"27108","DOI":"10.1016\/S0021-9258(18)47132-3","article-title":"N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing","volume":"269","author":"Platt","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2015.09.002_bb0140","first-page":"46","article-title":"The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?","volume":"124","author":"Shayman","year":"2013","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"issue":"5","key":"10.1016\/j.ymgme.2015.09.002_bb0145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"C. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.ymgme.2015.09.002_bb0150","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat","volume":"43","author":"Kamath","year":"2014","journal-title":"Skelet. Radiol."},{"issue":"6","key":"10.1016\/j.ymgme.2015.09.002_bb0155","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A Phase 2 study of eliglustat tartrate (Genz-112,638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ymgme.2015.09.002_bb0160","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112,638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ymgme.2015.09.002_bb0165","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2015.09.002_bb0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2015.09.002_bb0175","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ymgme.2015.09.002_bb0180","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/archinte.158.16.1754","article-title":"Gaucher disease: recommendations on diagnosis, evaluation, and monitoring","volume":"158","author":"Charrow","year":"1998","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.002_bb0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease-diagnosis and disease management algorithms","volume":"86","author":"Mistry","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"4 Suppl. 5","key":"10.1016\/j.ymgme.2015.09.002_bb0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgme.2015.09.002_bb0195","unstructured":"CERDELGA\u2122 (eliglustat) ([package insert]), Genzyme Corporation, a Sanofi Company, Waterford, Ireland, August 2014."},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.002_bb0200","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.ymgme.2014.12.272","article-title":"CYP2D6 phenotype-based dosing of eliglustat [abstract]","volume":"114","author":"Turpault","year":"2015","journal-title":"Molec. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.09.002_bb0205","series-title":"GeneReviews","article-title":"Gaucher disease","author":"Pastores","year":"2013"},{"issue":"4","key":"10.1016\/j.ymgme.2015.09.002_bb0210","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jog.12254","article-title":"Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease","volume":"40","author":"Elstein","year":"2014","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.002_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejogrb.2010.12.024","article-title":"The management of pregnancy in Gaucher disease","volume":"156","author":"Granovsky-Grisaru","year":"2011","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"12","key":"10.1016\/j.ymgme.2015.09.002_bb0220","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.clinthera.2010.11.008","article-title":"Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk","volume":"32","author":"Sekijima","year":"2010","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2015.09.002_bb0225","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.002_bb0230","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ymgme.2013.12.218","article-title":"Eliglustat adverse event data from a pooled analysis of four trials in Gaucher disease type 1 [abstract]","volume":"111","author":"Ross","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.09.002_bb0235","series-title":"Summary of Product Characteristics","author":"Zavesca (miglustat)","year":"2013"},{"issue":"9214","key":"10.1016\/j.ymgme.2015.09.002_bb0240","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.002_bb0245","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1750-1172-7-102","article-title":"Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study","volume":"7","author":"Cox","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2015.09.002_bb9000","first-page":"S69","article-title":"Tremor and peripheral neuropathy are infrequent and non-serious events in Gaucher type 1 patients treated with eliglustat [abstract]","volume":"114","author":"Lau","year":"2015","journal-title":"Molec. Genet. Metab."},{"issue":"8","key":"10.1016\/j.ymgme.2015.09.002_bb0250","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jbmr.1680","article-title":"Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"27","author":"Khan","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2015.09.002_bb0255","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","article-title":"Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3)","volume":"10","author":"Weinreb","year":"2015","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T13:27:56Z","timestamp":1653139676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719215300500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1096719215300500"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.09.002","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Shire Development LLC. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}